IL17A and psoriasis: The incidence of non-melanoma skin cancers in patients with psoriasis appears to be influenced by both disease-related factors and treatments, such as PUVA therapy and cyclosporine, while biologics targeting IL-17 and IL-23, and ustekinumab, because IL-12/23 treatment targets show no significant association with skin cancer risk [12].